{"entity":{"id":"nct05942300","kind":"trial","name":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","aka":[],"tldr":"A phase 1 trial of tulmimetostat (CPI-0209) with carboplatin in platinum-sensitive recurrent ovarian cancer, run by Lan Coffman, now recruiting.","summary":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer is a phase 1 interventional study registered as NCT05942300 by Lan Coffman, with Novartis Pharmaceuticals, National Cancer Institute (NCI) as collaborators; 30 participants are planned, it started on 2024-01-30; the registry gives 2028-07-31 as its primary completion date. Interventions recorded: CPI-0209, carboplatin. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05942300","url":"https://clinicaltrials.gov/study/NCT05942300"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["tulmimetostat","carboplatin"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05942300","phase":"1","setting":"Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","sponsor":"Lan Coffman","started":"2024-01-30","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05942300/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"tulmimetostat","kind":"drug","name":"Tulmimetostat","route":"/drugs/tulmimetostat/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}